CompletedPhase 2NCT01919619

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Issa Khouri, MD
M.D. Anderson Cancer Center
Intervention
Ipilimumab(biological)
Enrollment
41 enrolled
Eligibility
18-80 years · All sexes
Timeline
20132024

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01919619 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials